TABLE 1.

Bacterial strains used in this study

Strain or pairCubist strain designation(s)DescriptionReference or sourcea
S. aureus laboratory strains
    MW2CB1118Community-acquired MRSAb; sequenced genome, GenBank accession no. BA0000333; B. N. Kreiswirth
    MW2-CB1616CB1616-d1 to CB1616-d20Daily representatives from serial passage expt CB1616This study
    MW2-CB1617CB1617-d1 to CB1617-d20Daily representatives from serial passage expt CB1617This study
    MW2-CB1618CB1618-d1 to CB1618-d20Daily representatives from serial passage expt CB1618This study
    MW2-CiproRgrlA mutant from fifth day of ciprofloxacin serial passageThis study
S. aureus clinical isolates
    Pair 1
        CB1482MRSA, 9 December 2003 blood specimen; daptomycin MIC = 0.5 μg/ml13; LSI
        CB184MRSA, 11 May 2004 blood specimen; daptomycin MIC = 4 μg/ml13; LSI
    Pair 2
        CB1483MRSA, 31 December 2003 tibial tissue specimen; daptomycin MIC = 0.25 μg/ml13; LSI
        CB185MRSA, 18 February 2004 epidural tissue specimen; daptomycin MIC = 4 μg/ml13; LSI
    Pair 3
        CB1631MRSA, June 2004 blood specimen; daptomycin MIC = 0.5 μg/ml41; LSI
        CB1634MRSA, August 2004 T10-11; disk specimen; daptomycin MIC = 4 μg/ml41; LSI
  • a B. N. Kreiswirth, Public Health Research Institute, Newark, NJ; LSI, Laboratory Specialist, Inc., Westlake, OH.

  • b MRSA, methicillin-resistant S. aureus.